Conference abstractPublished 26 Jun 2022
Neoantigen-specific T-cell activation for the treatment of solid tumours
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The potential of personalized cancer immunotherapy using neoantigens (mutated proteins) has been highlighted by an increasing number of preclinical and clinical studies that show promising T-cell responses. It has been shown in various clinical trials that mRNA-engineered monocyte-derived dendritic cells (moDCs) are potent antigen-presenting cells that can activate antigen-specific T cells. Therefore, we optimized the manufacturing process of a cancer vaccine consisting of mRNA-modified, neoantigen-presenting moDCs, making it fully GMP compliant, allowing flexibility and possibility of automation. Monocytes were obtained by apheresis and differentiated ex vivo into moDCs. These were electroporated with two types of mRNA to generate the cancer vaccine designated TetraMixDC-NEO. The first type of mRNA encoded a single neoantigen (SNA), manufactured using an in-house developed proprietary synthetic DNA template, a flexible, time and cost-efficient strategy to encode and deliver SNA in an mRNA format.
Keywords
Subjects
Immunology & MicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. EuroSciCon does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalInsights in Immunology
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Karine Breckpot”
